Novel peptidic derivatives inhibiting gastric secretion, process for preparing them and drugs containing them

US4636490A · kind A · utility

Assignees

• Sanofi · FR
• CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE · FR

Inventors

• Jean Martinez · Caux, FR
• Jean-Pierre Bali · Montpellier, FR
• Bertrand Castro · Mamers, FR
• Dino Nisato · Pavia, IT
• Henri Demarne · Montpellier, FR

Key dates

• Filing date: Apr 6, 1984
• Grant date: Jan 13, 1987
• Expiry date: Apr 6, 2004

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K38/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to peptides of general formula: EQU R--A--Gly--Trp--B--Asp--NH.sub.2 (I) in which: PA1 Asp NH.sub.2 represents the amide in .alpha. position of the aspartic acid of formula: ##STR1## R represents hydrogen, a protector group of the terminal amine function such as t.butyloxy carbonyl (BOC), benzyloxy carbonyl (Z), lower alkanoyl, PA1 A designates: PA1 either tyrosine, tyrosine-O-sulfate, threonine or methionine; PA1 or a dipeptide selected from: --Ala--TYR--, --TYR--Thr--, --TYR Met--, TYR designating either of the 2 amino-acids tyrosine or tyrosine-O-sulfate; PA1 or a tripeptide selected from: --Glu--Ala--TYR--, Asp--TYR--Thr--, --Asp--TYR--MET--; PA1 or a tetrapeptide selected from: --Glu--Glu--Ala--TYR--, --Gln Asp--TYR--Thr--, --Arg--ASP--TYR--Met--; PA1 or a pentapeptide selected from: --Glu--Glu--Glu--Ala--TYR--, --Pyr--Gln--Asp--TYR--Thr--, --Asp--Arg--Asp--TYR--Met; PA1 B designates methionine, leucine or norleucine.